Pyro Pharmaceuticals

Pyro is a biotechnology company based in San Francisco that is pioneering the development of small molecule therapies targeting the pyroptosis pathway. The company's primary focus is on inhibiting Gasdermin D (GSDMD), a key protein responsible for the release of inflammatory cytokines and the execution of inflammatory cell death. By selectively blocking GSDMD, Pyro aims to provide a potent new approach for treating a variety of acute and chronic inflammatory diseases, including sepsis and inflammatory bowel disease. Founded in 2022 by world-renowned experts in innate immunity and protein engineering, the company is leveraging its proprietary platform to advance a pipeline of novel anti-inflammatory candidates. Pyro is currently in the pre-clinical stage and is supported by a syndicate of leading life science venture capital firms.